LY2409021 + clarithromycin

LY2409021 + clarithromycin is a **combination drug** composed of LY2409021, a novel and selective small-molecule glucagon receptor antagonist, and clarithromycin, a macrolide antibiotic. LY2409021 antagonizes the glucagon receptor, thereby lowering blood glucose by blocking glucagon’s stimulatory effect on hepatic glucose production, but it also increases liver fat and aminotransferases[1][2][4]. Clarithromycin inhibits bacterial protein synthesis by binding to the 50S ribosomal subunit, making it effective in treating various bacterial infections[3]. There is no evidence this drug combination is a uniquely branded product; it is simply the concurrent administration of both agents.

Other names

LY2409021LY-2409021LY 2409021clarithromycin6-O-methyl erythromycinBiaxin BidOmeclamoxPrevpacVoquezna 14 Day TriplepakVoquezna14 Day TriplepakVoquezna-14 Day Triplepak